<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Avicenna J Med Biotechnol</journal-id><journal-id journal-id-type="iso-abbrev">Avicenna J Med Biotechnol</journal-id><journal-id journal-id-type="pmc-domain-id">1980</journal-id><journal-id journal-id-type="pmc-domain">avicennajmb</journal-id><journal-id journal-id-type="publisher-id">AJMB</journal-id><journal-title-group><journal-title>Avicenna Journal of Medical Biotechnology</journal-title></journal-title-group><issn pub-type="ppub">2008-2835</issn><issn pub-type="epub">2008-4625</issn><publisher><publisher-name>Avicenna Research Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9017465</article-id><article-id pub-id-type="pmcid-ver">PMC9017465.1</article-id><article-id pub-id-type="pmcaid">9017465</article-id><article-id pub-id-type="pmcaiid">9017465</article-id><article-id pub-id-type="pmid">35509358</article-id><article-id pub-id-type="doi">10.18502/ajmb.v14i1.8167</article-id><article-id pub-id-type="publisher-id">AJMB-14-30</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>New Generation Vaccines for COVID-19 Based on Peptide, Viral Vector, Artificial Antigen Presenting Cell, DNA or mRNA</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Rezaei</surname><given-names initials="M">Marzieh</given-names></name><xref rid="AFF1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Nazari</surname><given-names initials="M">Mahboobeh</given-names></name><xref rid="AFF2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="C1" ref-type="corresp">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="AFF1"><label>1.</label>Department of Cell &amp; Molecular Biology and Microbiology, Faculty of Science and Biotechnology, University of Isfahan, Isfahan, Iran</aff><aff id="AFF2"><label>2.</label>Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</aff><author-notes><corresp id="C1"><label>*</label><bold>Corresponding author:</bold> Mahboobeh Nazari, Ph.D., Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran, <bold>Tel:</bold> +98 21 22432020, <bold>Fax:</bold> +98 21 22432021, E-mail:<email>Ma.nazari@avicenna.ac.ir</email>, <email>nazari1980azar@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2022</year></pub-date><volume>14</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">405618</issue-id><fpage>30</fpage><lpage>36</lpage><history><date date-type="received"><day>17</day><month>7</month><year>2021</year></date><date date-type="accepted"><day>20</day><month>9</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>03</day><month>05</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-12 04:25:13.833"><day>12</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright&#169; 2022 Avicenna Research Institute</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="AJMB-14-30.pdf"/><abstract><p>At present, effective vaccines have been developed as the most successful approaches for preventing widespread infectious disease. The global efforts are focusing with the aim of eliminating and overcoming the Coronavirus Disease 2019 (COVID-19) and are developing vaccines from the date it was announced as a pandemic disease. In this study, PubMed, Embase, Cochrane Library, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Clinicaltrial.gov" ext-link-type="uri">Clinicaltrial.gov</ext-link>, WHO reports, Science Direct, Scopus, Google Scholar, and Springer databases were searched for finding the relevant studies about the COVID-19 vaccines. This article provides an overview of multiple vaccines that have been manufactured from December 2020 up to April 2021 and also offers a perspective on their efficacy, safety, advantages, and limitations. Currently, there are several categories of COVID-19 vaccines based on Protein Subunit (PS), Inactivated Virus (IV), Virus Like Particle (VLP), Live Attenuated Virus (LAV), Viral Vector (replicating) (VVr) and Viral Vector (non-replicating) (VVnr) in progress or finalized as indicated by the WHO reporting of April 1, 2020.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>Pandemics</kwd><kwd>SARS-CoV-2</kwd><kwd>Vaccines</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>SARS-CoV-2, as the third zoonotic coronavirus after SARS-CoV and MERS-CoV <italic toggle="yes">causes</italic> an acute respiratory disease <xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>. Because of similar structure and gene homology (75&#8211;80% to SARS-Cov, 50% to MERSCov) this new emergent virus was named SARS CoV-2<xref rid="B3" ref-type="bibr">3</xref>. In addition, the receptor of SARS-CoV-2 spike protein to bind to a host cell is the same as the SARS-CoV spike one and is known as the Angiotensin-Converting Enzyme 2 (ACE2) <xref rid="B4" ref-type="bibr">4</xref>. Virus attachment to the host cell, subsequent infection, antigen presenting and prevention of infection of the SARS CoV-2 is described in a simple schematic figure (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Schematic illustration of viral vector vaccines against SARS CoV-2 and prevention of infection. Intramuscular (IM), Electroporation (EP).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="AJMB-14-30-g001.jpg"/></fig><p>Since the SARS-Cov-2 emerged and caused a novel disease in 2019, scientists from all over the world have been on the research to overcome this pandemic. Many efforts in regard to COVID-19 vaccines started with the development of vaccines from various platforms against SARSCoV-2 infection. Different categories of the developing vaccine candidates are shown in <xref rid="F2" ref-type="fig">figure 2</xref>. Most of them are based on the protein subunit specially the S-protein of SARSCoV-2 <xref rid="B5" ref-type="bibr">5</xref>.</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Different categories of SARS-CoV-2 Vaccines. Source: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> website; WHO.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="AJMB-14-30-g002.jpg"/></fig><p>These current vaccine candidates developed based on various platforms, including Inactivated Viral vaccines (IV), Live Attenuated Viral vaccines (LAV), peptide or subunit based vaccines, Virus-Like Particles (VLP), replicating viral vector vaccines, on-replicating viral vector vaccines, and DNA or mRNA-based vaccines. Two classical vaccines such as LAV and IV vaccines have high potential to elicit a protective immune response, while some limitations are associated with an infection and LAV vaccines can revert to wild type <xref rid="B6" ref-type="bibr">6</xref>.</p><p>The aim of this study was to focus on the new platforms of the current vaccine candidates. New vaccine strategies based on recombinant DNA and peptide technology would have more safety and stability than the current vaccine strategies and would promise the manufacture and development of new generation of vaccines in a more predictable approach <xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>. Some of these new generation platforms of vaccines are introduced in this study and include peptide based, nucleic acid based (DNA or RNA), viral vector and artificial Antigen Presenting Cells (aAPC) based vaccines <xref rid="B6" ref-type="bibr">6</xref>.</p><sec><title>Peptide based vaccines</title><p>Peptide vaccines are designed based on a single or highly immunogenic small epitopes. Most of COVID-19 candidate vaccines were designed based on protein subunit specially using the SARS-CoV-2 spike protein (S protein) or part of it as the immunogenic antigen. The glycoprotein S consists of S1 and S2 subunits. The Receptor Binding Domain (RBD) of the S protein potentially attaches to the receptor (ACE2) of the host cell <xref rid="B8" ref-type="bibr">8</xref>.</p><p>The following vaccines based on peptide subunit are conducted in clinical phase III for the prevention of COVID-19 (the registration numbers are included in <xref rid="T1" ref-type="table">table 1</xref>):
<table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p>Protein subunit vaccines, curent clinical phases</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"><bold>Vaccines types</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>Strategy of design</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>Clinical phase</bold></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>SARS-CoV-2 rS/Matrix M1-Adjuvant</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvant with Matrix M)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 2 and 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Recombinant SARS-CoV-2 vaccine</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(CHO Cell)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 2 and 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>SCB-2019 + AS03 or CpG 1018 adjuvant</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(Native like Trimeric subunit Spike Protein vaccine) plus Alum adjuvant</td><td align="center" valign="middle" rowspan="1" colspan="1">phase 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>COVAX-19&#174;</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">Recombinant spike protein + adjuvant</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>MF59</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">Adjuvanted SARS-CoV-2 Sclamp vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>MVC-COV1901</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(Spike-2P protein + adjuvant CpG 1018)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2 and Phase 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>FINLAY-FR1 anti-SARS-CoV-2 Vaccine</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(RBD + adjuvant)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2 and Phase 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>FINLAY-FR-2 anti-SARS-CoV-2 Vaccine</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(RBD chemically conjugated to tetanus toxoid plus adjuvant)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 2 and 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>EpiVacCorona</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 2 and 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Recombinant SARS-CoV-2 vaccine (Sf9 Cell)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">RBD (baculovirus production expressed in Sf9 cells) Recombinant SARS-CoV-2 vaccine (Sf9 Cell)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>IMP CoVac-1</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(SARS-CoV-2 HLA-DR peptides)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>UB-612</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(Multitope peptide based S1-RBD-protein based vaccine)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 2 and 2/3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>AdimrSC-2f</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(Recombinant RBD +/&#8722; Aluminium)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>CIGB-669</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(RBD+AgnHB)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>CIGB-66</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(RBD+aluminium hydroxide)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2 and phase 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Recombinant Sars-CoV-2 vaccine</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">Spike protein, Aluminum adjuvant</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Recombinant protein vaccine S-268019</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(Using Baculovirus expression vector system)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>SARS-CoV-2-RBD-Fc fusion protein</bold></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>COVAC-1 and COVAC-2 sub-unit vaccine</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">(Spike protein) + SWE adjuvant</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>GBP510</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">A recombinant surface protein vaccine with adjuvant AS03 (Aluminium hydroxide)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Razi Cov Pars</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">Recombinant spike protein</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>MF59</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">Adjuvanted SARS-CoV-2 Sclamp vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>SpFN (spike ferritin nanoparticle)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">Uses spike proteins with a liposomal formulation QS21 (ALFQ) adjuvant</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>EuCorVac-19</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">A spike protein using the recombinant protein technology and with an adjuvant</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>ReCOV</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">Recombinant two-component spike and RBD protein COVID-19 vaccine (CHO cell)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">Fusion Protein Vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 2</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>
Source: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> website; WHO.</p></fn></table-wrap-foot></table-wrap>
<list list-type="simple"><list-item><p>- The Full length recombinant SARS CoV-2 glycoprotein S vaccine adjuvanted with Matrix M</p></list-item><list-item><p>- The Recombinant SARS-CoV-2 vaccine (CHO Cell) in which the RBD chemically conjugates to tetanus toxoid plus adjuvant)</p></list-item><list-item><p>- The CIGB-66 vaccine based on RBD plus aluminium hydroxide adjuvant</p></list-item><list-item><p>- EpiVacCorona vaccine in which short fragments of a viral spike protein are conjugated to a large carrier protein (has just been approved and no published article could be found).</p></list-item></list>
</p><p>Thus, they might be advantageous due to targeting immunodominant epitopes which induce more immune responses based on neutralizing antibodies instead of larger proteins or whole inactivated virus <xref rid="B9" ref-type="bibr">9</xref>; safety during production, and safely administered to immuno-suppressed people <xref rid="B10" ref-type="bibr">10</xref>. In addition, these vaccine candidates are not potentially infectious compared to the whole virus <xref rid="B8" ref-type="bibr">8</xref>. Nonetheless, the T cell mediated immune response elicited by peptide based vaccine might be weaker in comparison to inactivated or live attenuated virus <xref rid="B11" ref-type="bibr">11</xref>. Actually, adjuvants are required to enhance antigen presenting to the host immune cells and improve the vaccine efficacy especially long term protection. Other disadvantages of the peptide based vaccines include: diminished uptake by Antigen Presenting Cells (APC) because of the small size of antigens, requiring more booster doses and adjuvants causing low immunogenicity, non-eliciting cellular responses, requiring confirmation of antigen integrity and restricting production due to low scalability <xref rid="B10" ref-type="bibr">10</xref>.</p></sec><sec><title>Viral vector vaccine</title><p>Several viral vector based vaccines are available and divided as replicating and non-replicating viral vectors including adenoviruses and poxviruses. In the non-replicating type of viral vector based vaccines, a safe virus with an attenuated state can deliver the desired antigen and trigger a protective immune response (both cell- and antibody-mediated) without any replication in host cell <xref rid="B12" ref-type="bibr">12</xref>.</p><p>Furthermore, viral vectored vaccines present the desired antigens and mimic a natural infection. The current COVID-19 vaccine based on the non-replicating and replicating viral vectors are shown in <xref rid="T2" ref-type="table">tables 2</xref> and <xref rid="T3" ref-type="table">3</xref>, respectively. Thus, these types of vaccines can provide a potent immune response due to inducing cytokines and co-stimulatory molecules. Finally, viral vectored vaccines provide long lasting expression of target genes <italic toggle="yes">in vivo</italic> compared to DNA vaccines <xref rid="B12" ref-type="bibr">12</xref>.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p>Viral vector (non-replicating) vaccines, clinical trials. Source: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> website; WHO</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Vaccines types</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Strategy of Design</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Clinical Phase</bold>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>ChAdOx1-S - (AZD1222) (Covishield)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Non-replicating ChAdOx1 Vector Vaccine make Spike glycoprotein (S)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 2/3, 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Recombinant novel coronavirus vaccine</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Adenovirus type 5 vector</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 2, 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Gam-COVID-Vac</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Adeno-based (rAd26-S+rAd5-S)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 2/3, 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>GRAd-COV2</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Replication defective Simian Adenovirus (GRAd) encoding S</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 2/3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>VXA-CoV2-1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Ad5 adjuvanted Oral Vaccine platform</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Human Adenovirus Type 5</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">hAd5 S+N vaccine (S-Fusion + N-ETSD). E2b- Deleted Adeno</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1, 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>COH04S1 (MVA-SARS-2-S)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Modified vaccinia ankara (sMVA) platform + synthetic SARS-CoV-2</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Chimpanzee Adenovirus serotype 68 (ChAd)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Self-amplifying mRNA (SAM) vectors expressing spike alone, or spike plus additional SARS-CoV-2 T cell epitopes</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>COVIVAC</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein +/&#8722; adjuvant CpG 1018</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>SC-Ad6-1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Adneviral vector vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><p>Viral vector (replicating) vaccines, clinical trial</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Vaccines types</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Strategy of Design</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Clinical Phase</bold>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>DelNS1-2019-nCoV-RBD-OPT1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Intranasal flu-based-RBD</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1 and 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Covid-19/aAPC vaccine</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune modulatory genes and the viral minigenes to the artificial antigen presenting cells (aAPCs)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Dendritic cell vaccine AV-COVID-19</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1, 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>AdCLD-CoV19</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Adenovirus vector</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>BBV154</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Adenoviral vector COVID-19 vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>NDV-HXP-S</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Newcastle disease virus (NDV) vector expressing the spike protein of SARS-CoV-2, with or without the adjuvant CpG 1018</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>
Source: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> website; WHO.</p></fn></table-wrap-foot></table-wrap><p>Adenoviruses as a non-replicating viral vectors are simple to produce (in 2 weeks it could be enough to treat a thousand mice and dozens of monkeys with a novel adenoviruses vaccine), easy to purify to high titer, genetically stable, easily stockpiled, relatively inexpensive, and can be delivered <italic toggle="yes">via</italic> aerosol, oral, intra dermal, and intramuscular routes. The aerosol route is considerably applicable when targeting a respiratory virus due to eliciting protective immune responses. It is also worth noting that viral vector vaccines tend to induce a robust response in both B cells and T cells <xref rid="B13" ref-type="bibr">13</xref> with a single dose and a good safety profile <xref rid="B10" ref-type="bibr">10</xref>.</p><p>Common to some vaccines, adverse effects of viral vector vaccines include fever, pneumonia, diarrhea, transient neutropenia and lymphopenia, fatigue, labored breathing, headaches, liver damage, and fasting hyperglycemia. It should be noted that rare but grave adverse side effects include Bell&#8217;s palsy, Guillain-Barre syndrome, gait disturbance, transverse myelitis, and an inflammatory condition in the spinal cord <xref rid="B13" ref-type="bibr">13</xref>.</p><p>The most successful type of COVID-19 vaccine based on non-replicating viral vector is ChAdOx1-S-(AZD1222) under the brand names Covishield as mentioned in <xref rid="T2" ref-type="table">table 2</xref> with high efficacy (76.0% following the first dose and 81.3% at the second dose) <xref rid="B14" ref-type="bibr">14</xref>.</p></sec><sec><title><italic toggle="yes">Artificial</italic> antigen-presenting cells <italic toggle="yes">(aAPC) vaccine</italic></title><p>The Dendritic Cells (DCs) are the most professional and specialized APCs that can be very efficient in activating T cells <xref rid="B15" ref-type="bibr">15</xref>. <italic toggle="yes">In situ</italic> delivery of cargo to DCs could be beneficial owing to a new standardized generation of vaccines with efficient scalability, stability, and more ability to induce humoral immune response <italic toggle="yes">vs.</italic> cell mediated immunity and high safety with low risk of adverse reactions through reducing the administered dose <xref rid="B16" ref-type="bibr">16</xref>. However, usage of the aAPC based vaccines have been limited because the process of isolation of specific DCs in this approach is labor-intensive and expensive <xref rid="B17" ref-type="bibr">17</xref>. In addition, the widespread use of aAPCs could be restricted by the fact that for definition and selection of MHC/peptide complexes identification of immunogenic antigens is required <xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>.</p></sec><sec><title>LV-SMENP-DC vaccine</title><p>LV-SMENP-DC vaccine is in phase 1/2 clinical trials with registration ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04276896">NCT04276896</ext-link> as clinical trials.gov reported (<xref rid="T2" ref-type="table">Table 2</xref>). Lent viral synthetic mini-gene vaccine is based on the selected, conserved and critical antigenic protein domain of SARS-CoV-2. In this approach, the DC is modified with LVs expressing SARS-CoV-2 minigene SMENP. Finally, the antigen specific CTLs will be stimulated by LV-DC expressing the desired antigens.</p></sec><sec><title>Nucleic acid-based vaccines</title><p>Nucleic acid-based vaccines can be classified as DNA or mRNA based vaccines that are capable to induce both humoral and cellular immune responses, but several doses are required <xref rid="B6" ref-type="bibr">6</xref>. Nucleic acid-based vaccines are likely to be the first priority of COVID-19 vaccines for entering clinical trials owing to their rapid adaptation to new emergence of virus <xref rid="B6" ref-type="bibr">6</xref>. The list of current vaccines based on the nucleic acid is shown in <xref rid="T4" ref-type="table">table 4</xref>.</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4.</label><caption><p>DNA or RNA based vaccines, clinical trial</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Vaccines types</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Strategy of Design</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Clinical Phase</bold>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>mRNA-1273</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">A lipid nanoparticle&#8211;encapsulated, nucleoside-modified messenger RNA that encodes the spike glycoprotein</td><td align="center" valign="middle" rowspan="1" colspan="1">Phases1/2, 2, 2/3 and 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>BNT162b2</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Nucleoside-modified RNA, contained within a lipid nanoparticle, which encodes the full-length spike</td><td align="center" valign="middle" rowspan="1" colspan="1">Phases1/2, 2, 2/3 and 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>CVnCoV Vaccine</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">An optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein, formulated within Lipid Nano-particles (LNPs)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phases 2, 2/3, 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>ARCT-021</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">self-transcribing and replicating mRNA (STARR&#8482;) with LUNAR&#174; lipid-mediated delivery technology</td><td align="center" valign="middle" rowspan="1" colspan="1">Phases1/2, 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>LNP-nCoVsaRNA</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">A purified, synthetic mRNA vaccine candidate encoding the S glycoprotein</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>SARS-CoV-2 mRNA vaccine (ARCoV)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">A nucleoside-modified mRNA vaccine in lipid-encapsulated form that encoded the SARS-CoV-2 RBD (mRNA-RBD)</td><td align="center" valign="middle" rowspan="1" colspan="1">Phases 1, 2, 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>ChulaCov19 mRNA vaccine</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">SARS-Cov2 Wild-type S-spike mRNA/lipid nanoparticle (LNP) vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>CoV2 SAM (LNP) vaccine.</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">A self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform + Spike antigen</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>mRNA-1273.351.</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">A lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1, 2, 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>MRT5500,</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">An mRNA vaccine candidate</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>HDT-301</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Self-replicating mRNA vaccine formulated as a lipid nanoparticle</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Covigenix VAX-001</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">DNA vaccines + proteo-lipid vehicle (PLV) formulation</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>CORVax</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Spike (S) Protein Plasmid DNA Vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>bacTRL</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Spike oral DNA vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>COVID-eVax</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">A candidate plasmid DNA vaccine of the Spike protein</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1/2</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>
Source: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> website; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Covid19.trackvaccines.org" ext-link-type="uri">Covid19.trackvaccines.org</ext-link>, WHO.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>DNA based vaccines</title><p>DNA vaccines contain a DNA construct that codes for specific antigenic protein from a pathogen. The genetically engineered plasmid containing the DNA sequence is injected into the body and taken up by cells. Then, the antigenic protein is synthesized from the DNA construct based on the genetic code.</p><p>Like live or attenuated viruses, DNA vaccines effectively elicit both MHC-I and MHC-II pathways allowing the stimulation of the CD8<sup>+</sup> and CD4<sup>+</sup> T cells <xref rid="B20" ref-type="bibr">20</xref> and inducing both humoral and cell-mediated immune responses <xref rid="B21" ref-type="bibr">21</xref>. Some advantages of the DNA based vaccines are efficient scalability, fast design and development, and being extremely safe <xref rid="B10" ref-type="bibr">10</xref>. Additional advantages of the DNA based vaccines are introduction of a vector encoding different antigens in a single vaccine; low-cost production, and high storage stability <xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B23" ref-type="bibr">23</xref>. In addition, no infectious agent handling is required and it can also induce humoral and cellular responses <xref rid="B10" ref-type="bibr">10</xref>.</p><p>In comparison to protein vaccines, DNA vaccines are considered to be low-cost vaccines. DNA vaccines can enhance stability for transportation and can be administered to immunocompromised patients <xref rid="B24" ref-type="bibr">24</xref>. DNA based vaccine is known as a new successful approach, but the widespread use of DNA vaccination is limited due to its poor efficacy <xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>, and low immunogenicity and may require multiple booster doses <xref rid="B24" ref-type="bibr">24</xref>. Currently, there is no nucleic acid vaccine approved. DNA vaccines require a special delivery platform <xref rid="B10" ref-type="bibr">10</xref>. Despite the fact that clinical trials using DNA vaccines in humans elicit both cellular and humoral responses, these responses are often not sufficient to prompt significant clinical benefits. Consequently, DNA vaccines have only been licensed for use in veterinary medicine<sup><xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B27" ref-type="bibr">27</xref></sup>.</p><p>Nevertheless, it would be important to focus on DNA vaccine optimization and delivery, including promoter design, codon optimization, adjuvants for use in humans, use of electroporation, and prime/boost immunization for refined vaccine design <xref rid="B28" ref-type="bibr">28</xref>. Regarding DNA vaccine administration, studies have shown that <italic toggle="yes">in vivo</italic> immune responses can be improved due to increased antigen delivery by electroporation (up to 1000-fold greater than delivery of naked DNA alone) <xref rid="B29" ref-type="bibr">29</xref>. New advances have been reported in the immunization routes <xref rid="B30" ref-type="bibr">30</xref>, for example the intradermal electroporation DNA delivery showed well tolerated, dose sparing and improving humoral immune responses in comparison to conventional intramuscular electroporation <xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>.</p><p>nCov vaccine as DNA based vaccine against COVID-19 is in phase 3 of clinical trials with registration ID nCov vaccine CTRI/2020/07/026352 (<xref rid="T4" ref-type="table">Table 4</xref>) and two others (CTRI/2020/07/026352; CTRI/2021/03/032051) are in phase 1/2 (<xref rid="T4" ref-type="table">Table 4</xref>).</p></sec><sec><title>mRNA based vaccine</title><p>mRNA-based vaccines are similar to DNA vaccines, except that the transcriptional stage is eliminated <xref rid="B6" ref-type="bibr">6</xref>. mRNA based vaccines are beneficial in comparison with conventional vaccines (<italic toggle="yes">e.g.</italic> subunit, killed and live attenuated virus, as well as DNA-based vaccines) because of its high potential for low cost production with high yields of <italic toggle="yes">in vitro</italic> transcription, fast development and safe and repeated administration. Easy and uncomplicated formulation of mRNA into carrier molecules such as lipid nanoparticles, causes fast uptake and expression and finally enables entry of the mRNA into cells <xref rid="B33" ref-type="bibr">33</xref>.</p><p>mRNA-based vaccines represent naturally immunostimulatory activity which is recognized by all cell surfaces, endosomal and cytosolic immune receptors. It also could provide adjuvant activity and thus elicit strong T and B cell immune responses <xref rid="B34" ref-type="bibr">34</xref>. mRNA vaccines can be considered as highly safe vaccines because there is extremely low risk of infection or muta-genesis. mRNA based vaccines could be restricted due to difficult condition of storage and transporting and may need extremely low temperatures. mRNA vaccines exhibit instability and require storage at &lt;&#8722;20&#176; <italic toggle="yes">C</italic><xref rid="B34" ref-type="bibr">34</xref>.</p><p>High efficacy of mRNA based vaccines would be achieved owing to more stability of mRNA and high translatability through various modifications in mRNA structure. Additionally, degradation of mRNA has been normally done by cellular processes, and <italic toggle="yes">in vivo</italic> half-life of mRNA can be increased through these modifications <xref rid="B35" ref-type="bibr">35</xref>.</p><p>It is crucial to consider that unmodified mRNA itself is considerably sensitive, rapidly degradable, and highly immunogenic with high probability of activating a variety of pathogen-associated molecular pattern sensors <xref rid="B34" ref-type="bibr">34</xref>. Researchers showed that some modifications to nucleosides in mRNA molecules could improve the translatability and safety of mRNA vaccines as well as half-life <xref rid="B36" ref-type="bibr">36</xref>. They reported that the incorporation of N1-methyl-pseudouridine (m1&#936;) in place of uridine increased the translatability (10-fold) over unmodified mRNA. This m1&#936; mRNA modification was included in the vaccine designing of two recently licensed mRNA vaccines mRNA-1273 and BNT162b2 <xref rid="B37" ref-type="bibr">37</xref>&#8211;<xref rid="B39" ref-type="bibr">39</xref>.</p><p>As shown in <xref rid="F3" ref-type="fig">figure 3</xref>, new research by Lombardi <italic toggle="yes">et al</italic> showed that the BNT162b2 (Pfizer) and mRNA-1273 (MODERNA/NIH) vaccines displayed an excellent efficacy (94%) <xref rid="B40" ref-type="bibr">40</xref>. Safety data of mRNA BNT-162b2 and mRNA-1273 vaccines indicated that these vaccines are safe without any adverse reactions or health complications <xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B39" ref-type="bibr">39</xref>. Self-replicating RNA vaccines have high potency to express more antigens per cell and stimulate protective immune response with lower dose in comparison with classic RNA vaccines <xref rid="B41" ref-type="bibr">41</xref>.</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Sinovac efficacy trials have announced efficacies (for the same product) of 50%, 65%, 78% and 91% <xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B26" ref-type="bibr">26</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="AJMB-14-30-g003.jpg"/></fig></sec></sec><sec sec-type="conclusion"><title>Conclusion</title><p>Appearance of various subtypes of SARS-COV-2 virus due to different mutations, antigenic shift and antigenic drift may allow the virus to deceive the immune system even after the administration of the vaccine and offer insights into virus evolution. Dorp <italic toggle="yes">et al</italic> detected 198 mutations of SARS-COV-2 from the 7500 positive samples which caused the emergence of this novel virus with genomic diversity. Therefore, it can be concluded that these 198 mutations, which originated separately may indicate the evolution of the virus within the human host <xref rid="B42" ref-type="bibr">42</xref>.</p><p>Another point to consider is that, the benefits of an effective vaccine must outweigh the attributed known risks before its administration. Moreover, both safety and efficacy of the vaccine can be considered at least one year after administration. It is impossible to predict which types of candidate vaccines will be successful without running large-scale clinical trials.</p><p>In addition, the effectiveness of every vaccine, regardless of its targeting abilities, is also characterized by the dose, size, surface charge, cargo, using adjuvants, route of administration, and the species to which it is delivered.</p><sec><title>This review has some limitations which are presented as following future directions</title><p>Future directions of the COVID-19 vaccine must consider the optimizations of the COVID-19 vaccine which are known as the durability, dose, schedule and boosters; the effectiveness of the vaccine (Real word evidence or Herd immunity); safety (long term) and also the surveillance of the new subtypes (mutants) of virus.</p></sec></sec></body><back><ack><title>Acknowledgement</title><p>We would like to appreciate the Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR. This work was supported by a grant number of 990204-009 from Avicenna Research Institute.</p></ack><fn-group><fn fn-type="COI-statement"><p>
<bold>Conflict of Interest</bold>
</p><p>The authors declare no competing interests regarding this article.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drosten</surname><given-names>C</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>S</given-names></name><name name-style="western"><surname>Preiser</surname><given-names>W</given-names></name><name name-style="western"><surname>Van Der Werf</surname><given-names>S</given-names></name><name name-style="western"><surname>Brodt</surname><given-names>HR</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identification of a novel coronavirus in patients with severe acute respiratory syndrome</article-title>. <source>New Eng J Med</source><year>2003</year>;<volume>348</volume>(<issue>20</issue>):<fpage>1967</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">12690091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa030747</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaki</surname><given-names>AM</given-names></name><name name-style="western"><surname>Van Boheemen</surname><given-names>S</given-names></name><name name-style="western"><surname>Bestebroer</surname><given-names>TM</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>AD</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>RA.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title>. <source>New Eng J Med</source><year>2012</year>;<volume>367</volume>(<issue>19</issue>):<fpage>1814</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">23075143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1211721</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><etal/></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title>. <source>N Engl J Med</source><year>2020</year><month>Feb</month><day>20</day>;<volume>382</volume>(<issue>8</issue>):<fpage>727</fpage>&#8211;<lpage>733</lpage>.<pub-id pub-id-type="pmid">31978945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmcid">PMC7092803</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>AC</given-names></name><name name-style="western"><surname>Park</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wall</surname><given-names>A</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>AT</given-names></name><name name-style="western"><surname>Veesler</surname><given-names>D.</given-names></name></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title>. <source>Cell</source><year>2020</year>;<volume>181</volume>(<issue>2</issue>):<fpage>281</fpage>&#8211;<lpage>92.e6</lpage>.<pub-id pub-id-type="pmid">32155444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhama</surname><given-names>K</given-names></name><name name-style="western"><surname>Sharun</surname><given-names>K</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>R</given-names></name><name name-style="western"><surname>Dadar</surname><given-names>M</given-names></name><name name-style="western"><surname>Malik</surname><given-names>YS</given-names></name><name name-style="western"><surname>Singh</surname><given-names>KP</given-names></name><etal/></person-group><article-title>COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics</article-title>. <source>Hum Vaccin Immunother</source><year>2020</year>;<volume>16</volume>(<issue>6</issue>):<fpage>1232</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32186952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2020.1735227</pub-id><pub-id pub-id-type="pmcid">PMC7103671</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Riel</surname><given-names>D</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name></person-group><article-title>Next-generation vaccine platforms for COVID-19</article-title>. <source>Nat Mater</source><year>2020</year>;<volume>19</volume>(<issue>8</issue>):<fpage>810</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="pmid">32704139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41563-020-0746-0</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dom&#237;nguez-Andr&#233;s</surname><given-names>J</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R</given-names></name><name name-style="western"><surname>Divangahi</surname><given-names>M</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG.</given-names></name></person-group><article-title>Designing the next generation of vaccines: relevance for future pandemics</article-title>. <source>mBio</source><year>2020</year>;<volume>11</volume>(<issue>6</issue>):<fpage>e02616</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">33443120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.02616-20</pub-id><pub-id pub-id-type="pmcid">PMC8534290</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tenchov</surname><given-names>R</given-names></name><name name-style="western"><surname>Smoot</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name></person-group><article-title>A comprehensive review of the global efforts on COVID-19 vaccine development</article-title>. <source>ACS Cent Sci</source><year>2021</year>;<volume>7</volume>(<issue>4</issue>):<fpage>512</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">34056083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acscentsci.1c00120</pub-id><pub-id pub-id-type="pmcid">PMC8029445</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghaffari-Nazari</surname><given-names>H</given-names></name><name name-style="western"><surname>Tavakkol-Afshari</surname><given-names>J</given-names></name><name name-style="western"><surname>Jaafari</surname><given-names>MR</given-names></name><name name-style="western"><surname>Tahaghoghi-Hajghorbani</surname><given-names>S</given-names></name><name name-style="western"><surname>Masoumi</surname><given-names>E</given-names></name><name name-style="western"><surname>Jalali</surname><given-names>SA.</given-names></name></person-group><article-title>Improving multi-epitope long peptide vaccine potency by using a strategy that enhances CD4+ T help in BALB/c mice</article-title>. <source>PloS One</source><year>2015</year>;<volume>10</volume>(<issue>11</issue>):<fpage>e0142563</fpage>.<pub-id pub-id-type="pmid">26556756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0142563</pub-id><pub-id pub-id-type="pmcid">PMC4640540</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyriakidis</surname><given-names>NC</given-names></name><name name-style="western"><surname>L&#243;pez-Cort&#233;s</surname><given-names>A</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>EV</given-names></name><name name-style="western"><surname>Grimaldos</surname><given-names>AB</given-names></name><name name-style="western"><surname>Prado</surname><given-names>EO.</given-names></name></person-group><article-title>SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates</article-title>. <source>NPJ Vaccines</source><year>2021</year>;<volume>6</volume>(<issue>1</issue>):<fpage>28</fpage>.<pub-id pub-id-type="pmid">33619260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-021-00292-w</pub-id><pub-id pub-id-type="pmcid">PMC7900244</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malonis</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Lai</surname><given-names>JR</given-names></name><name name-style="western"><surname>Vergnolle</surname><given-names>O.</given-names></name></person-group><article-title>Peptide-based vaccines: current progress and future challenges</article-title>. <source>Chem Rev</source><year>2019</year>;<volume>120</volume>(<issue>6</issue>):<fpage>3210</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="pmid">31804810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.chemrev.9b00472</pub-id><pub-id pub-id-type="pmcid">PMC7094793</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert-Guroff</surname><given-names>M.</given-names></name></person-group><article-title>Replicating and non-replicating viral vectors for vaccine development</article-title>. <source>Curr Opin Biotechnol</source><year>2007</year>;<volume>18</volume>(<issue>6</issue>):<fpage>546</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">18063357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.copbio.2007.10.010</pub-id><pub-id pub-id-type="pmcid">PMC2245896</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kremer</surname><given-names>EJ.</given-names></name></person-group><article-title>Pros and cons of adenovirus-based SARSCoV-2 vaccines</article-title>. <source>MoL Ther</source><year>2020</year>;<volume>28</volume>(<issue>11</issue>):<fpage>2303</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">33065038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2020.10.002</pub-id><pub-id pub-id-type="pmcid">PMC7546260</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>SAC</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Weckx</surname><given-names>LY</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials</article-title>. <source>Lancet</source><year>2021</year>;<volume>397</volume>(<issue>10277</issue>):<fpage>881</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">33617777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00432-3</pub-id><pub-id pub-id-type="pmcid">PMC7894131</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhardwaj</surname><given-names>N</given-names></name><name name-style="western"><surname>Young</surname><given-names>JW</given-names></name><name name-style="western"><surname>Nisanian</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Baggers</surname><given-names>J</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>R.</given-names></name></person-group><article-title>Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses</article-title>. <source>J Exp Med</source><year>1993</year>;<volume>178</volume>(<issue>2</issue>):<fpage>633</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">8340760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.178.2.633</pub-id><pub-id pub-id-type="pmcid">PMC2191121</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goyvaerts</surname><given-names>C</given-names></name><name name-style="western"><surname>Breckpot</surname><given-names>K.</given-names></name></person-group><article-title>Pros and cons of antigen-presenting cell targeted tumor vaccines</article-title>. <source>J Immunol Res</source><year>2015</year>;<fpage>2015</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/785634</pub-id><pub-id pub-id-type="pmcid">PMC4637118</pub-id><pub-id pub-id-type="pmid">26583156</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohn</surname><given-names>L</given-names></name><name name-style="western"><surname>Delamarre</surname><given-names>L.</given-names></name></person-group><article-title>Dendritic cell-targeted vaccines</article-title>. <source>Front Immunol</source><year>2014</year>;<volume>5</volume>:<fpage>255</fpage>.<pub-id pub-id-type="pmid">24910635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2014.00255</pub-id><pub-id pub-id-type="pmcid">PMC4039009</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Q</given-names></name><name name-style="western"><surname>Igy&#225;rt&#243;</surname><given-names>BZ.</given-names></name></person-group><article-title>One-step artificial antigen presenting cell-based vaccines induce potent effector CD8 T cell responses</article-title>. <source>Sci Rep</source><year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>18949</fpage>.<pub-id pub-id-type="pmid">31831802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-55286-5</pub-id><pub-id pub-id-type="pmcid">PMC6908577</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>MS</given-names></name><name name-style="western"><surname>Darrah</surname><given-names>D</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>D</given-names></name><name name-style="western"><surname>Halpern</surname><given-names>S</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>A</given-names></name><name name-style="western"><surname>Voland</surname><given-names>J</given-names></name><etal/></person-group><article-title>Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope</article-title>. <source>J Clin Oncol</source><year>2002</year>;<volume>20</volume>(<issue>4</issue>):<fpage>1075</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">11844833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2002.20.4.1075</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Godillot</surname><given-names>A</given-names></name><name name-style="western"><surname>Madaio</surname><given-names>MP</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D</given-names></name><name name-style="western"><surname>Williams</surname><given-names>W.</given-names></name></person-group><article-title>Vaccination against pathogenic cells by DNA inoculation</article-title>. <source>Curr Top Microbiol Immunol</source><year>1998</year>;<volume>226</volume>:<fpage>21</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">9479833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-642-80475-5_2</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hobernik</surname><given-names>D</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name></person-group><article-title>DNA vaccines&#8212;how far from clinical use?</article-title><source>Int J Mol Sci</source><year>2018</year>;<volume>19</volume>(<issue>11</issue>):<fpage>3605</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms19113605</pub-id><pub-id pub-id-type="pmcid">PMC6274812</pub-id><pub-id pub-id-type="pmid">30445702</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>PW</given-names></name><name name-style="western"><surname>Lam</surname><given-names>JKW.</given-names></name></person-group><article-title>Intranasal DNA vaccine for protection against respiratory infectious diseases: the delivery perspectives</article-title>. <source>Pharmaceutics</source><year>2014</year>;<volume>6</volume>(<issue>3</issue>):<fpage>378</fpage>&#8211;<lpage>415</lpage>.<pub-id pub-id-type="pmid">25014738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics6030378</pub-id><pub-id pub-id-type="pmcid">PMC4190526</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silveira</surname><given-names>MM</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>TL</given-names></name><name name-style="western"><surname>Schuch</surname><given-names>RA</given-names></name><name name-style="western"><surname>McBride</surname><given-names>AJA</given-names></name><name name-style="western"><surname>Dellagostin</surname><given-names>OA</given-names></name><name name-style="western"><surname>Hartwig</surname><given-names>DD.</given-names></name></person-group><article-title>DNA vaccines against leptospirosis: A literature review</article-title>. <source>Vaccine</source><year>2017</year>;<volume>35</volume>(<issue>42</issue>): <fpage>5559</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="pmid">28882437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.08.067</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>SA</given-names></name><name name-style="western"><surname>Jhan</surname><given-names>YY</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>CJ.</given-names></name></person-group><article-title>Engineering DNA vaccines against infectious diseases</article-title>. <source>Acta biomater</source><year>2018</year>;<volume>80</volume>:<fpage>31</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="pmid">30172933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2018.08.033</pub-id><pub-id pub-id-type="pmcid">PMC7105045</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leitner</surname><given-names>WW</given-names></name><name name-style="western"><surname>Ying</surname><given-names>H</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>NP.</given-names></name></person-group><article-title>DNA and RNA-based vaccines: principles, progress and prospects</article-title>. <source>Vaccine</source><year>1999</year>;<volume>18</volume>(<issue>9&#8211;10</issue>):<fpage>765</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">10580187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(99)00271-6</pub-id><pub-id pub-id-type="pmcid">PMC1986720</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leclerc</surname><given-names>C</given-names></name><name name-style="western"><surname>Ronco</surname><given-names>J.</given-names></name></person-group><article-title>New approaches in vaccine development</article-title>. <source>Immunol Today</source><year>1998</year>;<volume>19</volume>(<issue>7</issue>):<fpage>300</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="pmid">9666601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0167-5699(98)01282-1</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coban</surname><given-names>C</given-names></name><name name-style="western"><surname>Kobiyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Jounai</surname><given-names>N</given-names></name><name name-style="western"><surname>Tozuka</surname><given-names>M</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>KJ.</given-names></name></person-group><article-title>DNA vaccines: a simple DNA sensing matter?</article-title><source>Hum Vaccin Immunother</source><year>2013</year>;<volume>9</volume>(<issue>10</issue>):<fpage>2216</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">23912600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.25893</pub-id><pub-id pub-id-type="pmcid">PMC3906407</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Saade</surname><given-names>F</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>The future of human DNA vaccines</article-title>. <source>J Biotechnol</source><year>2012</year>;<volume>162</volume>(<issue>2&#8211;3</issue>):<fpage>171</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">22981627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbiotec.2012.08.012</pub-id><pub-id pub-id-type="pmcid">PMC3511659</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sardesai</surname><given-names>NY</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>DB.</given-names></name></person-group><article-title>Electroporation delivery of DNA vaccines: prospects for success</article-title>. <source>Curr Opin Immunol</source><year>2011</year>;<volume>23</volume>(<issue>3</issue>):<fpage>421</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21530212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coi.2011.03.008</pub-id><pub-id pub-id-type="pmcid">PMC3109217</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>TR</given-names></name><name name-style="western"><surname>Schultheis</surname><given-names>K</given-names></name><name name-style="western"><surname>Kiosses</surname><given-names>WB</given-names></name><name name-style="western"><surname>Amante</surname><given-names>DH</given-names></name><name name-style="western"><surname>Mendoza</surname><given-names>JM</given-names></name><name name-style="western"><surname>Stone</surname><given-names>JC</given-names></name><etal/></person-group><article-title>DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response</article-title>. <source>Mol Ther Methods Clin Dev</source><year>2014</year>;<volume>1</volume>:<fpage>14054</fpage>.<pub-id pub-id-type="pmid">26052522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mtm.2014.54</pub-id><pub-id pub-id-type="pmcid">PMC4448738</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Banglore</surname><given-names>P</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>KA</given-names></name><name name-style="western"><surname>Schmaljohn</surname><given-names>CS</given-names></name><name name-style="western"><surname>Schultheis</surname><given-names>K</given-names></name><name name-style="western"><surname>Pugh</surname><given-names>H</given-names></name><etal/></person-group><article-title>Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques</article-title>. <source>Hum Vaccin Immunother</source><year>2019</year>; <volume>15</volume>(<issue>9</issue>):<fpage>2066</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">31071008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2019.1616499</pub-id><pub-id pub-id-type="pmcid">PMC6773375</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tebas</surname><given-names>P</given-names></name><name name-style="western"><surname>Kraynyak</surname><given-names>KA</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Maslow</surname><given-names>JN</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>MP</given-names></name><name name-style="western"><surname>Sylvester</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Intradermal SynCon&#174; Ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers</article-title>. <source>J Infect Dis</source><year>2019</year>;<volume>220</volume> (<issue>3</issue>):<fpage>400</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">30891607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiz132</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kauffman</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Webber</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>DG.</given-names></name></person-group><article-title>Materials for non-viral intracellular delivery of messenger RNA therapeutics</article-title>. <source>J Control Release</source><year>2016</year>;<volume>240</volume>:<fpage>227</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">26718856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2015.12.032</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Porter</surname><given-names>FW</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccines&#8212;a new era in vaccinology</article-title>. <source>Nat Rev Drug Discov</source><year>2018</year>;<volume>17</volume>(<issue>4</issue>):<fpage>261</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thess</surname><given-names>A</given-names></name><name name-style="western"><surname>Grund</surname><given-names>S</given-names></name><name name-style="western"><surname>Mui</surname><given-names>BL</given-names></name><name name-style="western"><surname>Hope</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Baumhof</surname><given-names>P</given-names></name><name name-style="western"><surname>Fotin-Mleczek</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals</article-title>. <source>Mol Ther</source><year>2015</year>;<volume>23</volume>(<issue>9</issue>): <fpage>1456</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">26050989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2015.103</pub-id><pub-id pub-id-type="pmcid">PMC4817881</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karik&#243;</surname><given-names>K</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>FA</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>J</given-names></name><name name-style="western"><surname>Kato</surname><given-names>H</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name><etal/></person-group><article-title>Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability</article-title>. <source>Mol ther</source><year>2008</year>;<volume>16</volume>(<issue>11</issue>):<fpage>1833</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">18797453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2008.200</pub-id><pub-id pub-id-type="pmcid">PMC2775451</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bettini</surname><given-names>E</given-names></name><name name-style="western"><surname>Locci</surname><given-names>M.</given-names></name></person-group><article-title>SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond</article-title>. <source>Vaccines (Basel)</source><year>2021</year>;<volume>9</volume>(<issue>2</issue>):<fpage>147</fpage>.<pub-id pub-id-type="pmid">33673048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9020147</pub-id><pub-id pub-id-type="pmcid">PMC7918810</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>E.</given-names></name></person-group><article-title>Why Oxford's positive COVID vaccine results are puzzling scientists</article-title>. <source>Nature</source><year>2020</year>;<volume>588</volume>(<issue>7836</issue>): <fpage>16</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">33230278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-020-03326-w</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>FP</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title>. <source>N Engl J Med</source><year>2020</year>;<volume>383</volume>(<issue>27</issue>):<fpage>2603</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lombardi</surname><given-names>A</given-names></name><name name-style="western"><surname>Bozzi</surname><given-names>G</given-names></name><name name-style="western"><surname>Ungaro</surname><given-names>R</given-names></name><name name-style="western"><surname>Villa</surname><given-names>S</given-names></name><name name-style="western"><surname>Castelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Mangioni</surname><given-names>D</given-names></name><etal/></person-group><article-title>MINI REVIEW Immunological consequences of immunization with COVID-19 mRNA vaccines: Preliminary results</article-title>. <source>Front Immunol</source><year>2021</year>;<volume>12</volume>: <fpage>657711</fpage>.<pub-id pub-id-type="pmid">33777055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.657711</pub-id><pub-id pub-id-type="pmcid">PMC7994748</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogel</surname><given-names>AB</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>L</given-names></name><name name-style="western"><surname>Kinnear</surname><given-names>E</given-names></name><name name-style="western"><surname>Busse</surname><given-names>D</given-names></name><name name-style="western"><surname>Erbar</surname><given-names>S</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses</article-title>. <source>Mol Ther</source><year>2018</year>;<volume>26</volume>(<issue>2</issue>): <fpage>446</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">29275847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2017.11.017</pub-id><pub-id pub-id-type="pmcid">PMC5835025</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dorp</surname><given-names>L</given-names></name><name name-style="western"><surname>Acman</surname><given-names>M</given-names></name><name name-style="western"><surname>Richard</surname><given-names>D</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>LP</given-names></name><name name-style="western"><surname>Ford</surname><given-names>CE</given-names></name><name name-style="western"><surname>Ormond</surname><given-names>L</given-names></name><etal/></person-group><article-title>Emergence of genomic diversity and recurrent mutations in SARS-CoV-2</article-title>. <source>Infect Genet Evol</source><year>2020</year>;<volume>83</volume>:<fpage>104351</fpage>.<pub-id pub-id-type="pmid">32387564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.meegid.2020.104351</pub-id><pub-id pub-id-type="pmcid">PMC7199730</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>